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Salicylate (SAL) has been recently implicated in the antidiabetic effect in 
humans. We assessed whether 5′-AMP-activated protein kinase (AMPK) in 
skeletal muscle is involved in the effect of SAL on glucose homeostasis. Rat 
fast-twitch epitrochlearis and slow-twitch soleus muscles were incubated in 
buffer containing SAL. Intracellular concentrations of SAL increased rapidly 
(<5 min) in both skeletal muscles, and the Thr172 phosphorylation of the α 
subunit of AMPK increased in a dose- and time-dependent manner. SAL 
increased both AMPKα1 and AMPKα2 activities. These increases in enzyme 
activity were accompanied by an increase in the activity of 
3-O-methyl-D-glucose transport, and decreases in ATP, phosphocreatine, and 
glycogen contents. SAL did not change the phosphorylation of insulin 
receptor signaling including insulin receptor substrate 1, Akt, and p70 
ribosomal protein S6 kinase. These results suggest that SAL may be 
transported into skeletal muscle and may stimulate AMPK and glucose 
transport via energy deprivation in multiple muscle types. Skeletal muscle 
AMPK might be part of the mechanism responsible for the metabolic 
improvement induced by SAL. 
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 SAL, salicylate; T2D, type 2 diabetes mellitus; AMPK, 5′-AMP-activated 
protein kinase; KRB, Krebs–Ringer bicarbonate buffer; DNP, 
2,4-dinitrophenol; AICAR: 
5-aminoimidazole-4-carboxamide-1-α-D-ribonucleoside; IRS1, insulin 
receptor substrate 1; p70S6K, p70 ribosomal protein S6 kinase; GLUT4, 
glucose transporter 4; AMPKα1:, α1-containing AMPK complex; AMPKα2:, 
α2-containing AMPK complex; 3MG, 3-O-methyl-D-glucose; PCr, 
phosphocreatine; SE, standard error. 
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 1. Introduction 
 
Salicylate (SAL), a willow bark product, has been used as an 
anti-inflammatory agent since ancient times. SAL induces systemic 
anti-inflammatory effects by suppressing cyclooxygenase, resulting in 
decreased production of proinflammatory mediators such as prostaglandins 
[1].  
Interestingly, a number of clinical studies have suggested that SAL 
stimulates metabolic processes and improves glucose homeostasis in humans. 
Goldfine et al [2] demonstrated that a 14-week oral SAL treatment (salsalate 
3.0–4.0 g/day) significantly improved glycemic control in patients with type 2 
diabetes (T2D). The mean changes in the hemoglobin A1c level were −0.36% 
at 3.0 g/day, −0.34% at 3.5 g/day, and −0.49% at 4.0 g/day compared with the 
placebo. More recently, Goldfine et al [3] demonstrated that long-term (48 
weeks) oral SAL treatment (salsalate 3.5 g/day) significantly improved 
glycemic control in people with T2D. The mean hemoglobin A1c level after 48 
weeks was 0.37% lower in the SAL group than in the placebo group. 
We hypothesized that 5′-AMP-activated protein kinase (AMPK) in 
skeletal muscle plays a pivotal role in the antidiabetic effect of SAL. AMPK is 
a metabolite-sensing protein kinase and is acutely activated by 
energy-depriving stimuli in skeletal muscle such as exercise (contraction). 
Although Hawley et al [4] first reported that AMPK is phosphorylated in 
mouse soleus muscle 90 min after an intraperitoneal injection of SAL, to our 
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 knowledge, no study has provide fundamental evidence of AMPK activation 
in skeletal muscle. Thus, the primary aim of the current study was to 
determine whether SAL is taken up into skeletal muscle cells and, if so, 
whether it stimulates AMPK by altering the energy status. We examined two 
different types of isolated rat skeletal muscles: fast-glycolytic epitrochlearis 
[5] and slow-oxidative soleus muscles [6]. 
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 2. Materials and Methods 
 
2.1. Animals 
Male Sprague Dawley rats weighing 150 g (Shimizu Breeding 
Laboratories, Kyoto, Japan) fed a standard chow and water ad libitum were 
randomly divided into experimental groups after an overnight fast. The 
experimental protocols were approved by Kyoto University Graduate School 
of Human and Environmental Studies, and Kyoto University Radioisotope 
Research Center. 
 
2.2. Muscle preparation in vitro 
Muscle incubation was conducted as we have previously described [7]. 
Epitrochlearis and soleus muscles were isolated after cervical dislocation. 
The muscles were attached to an incubation apparatus and preincubated in 
Krebs-Ringer bicarbonate buffer (KRB) containing 2 mM pyruvate for 40 min. 
Muscles were then transferred to buffer containing various concentrations 
(0–10 mM) of SAL (sodium salicylate) for 30 min or buffer containing 5 mM 
SAL for up to 60 min. Muscles were also incubated in buffer containing 0.5 
mM 2,4-dinitrophenol (DNP) for 10 min or 2 mM 
5-aminoimidazole-4-carboxamide-1-α-D-ribonucleoside (AICAR) for 30 min 
for maximal stimulation of AMPK, or 1 µM insulin for 30 min for maximal 
stimulation of insulin signaling. The muscles samples were either used for 
SAL transport and glucose transport measurements, or they were frozen in 
6 
 
 liquid nitrogen for other assays. 
 
2.3. Western blotting 
Western blot analysis was performed as we have previously described [7]. 
Frozen muscle was homogenized in buffer containing 1% Triton X-100, 20 
mM Tris·HCl (pH 7.4), 250 mM sucrose, 50 mM NaCl, 2 mM dithiothreitol, 50 
mM NaF, 5 mM sodium pyrophosphate, 50 mg/l trypsin inhibitor, 4 mg/l 
leupeptin, 0.1 mM benzamidine, 0.5 mM phenylmethylsulfonyl fluoride, and 
1 mM Na2VO4 (Buffer A) at 4°C. The homogenate was centrifuged at 16,000 g 
for 40 min at 4°C. Aliquots of the supernatant (10 µg of protein) were 
separated by SDS-PAGE and transferred to a polyvinylidene difluoride 
membrane. The membrane was blocked with skim milk and then incubated 
overnight at 4°C with primary antibodies. The primary antibodies were to 
AMPK α subunit (#2532; Cell Signaling Technology, Danvers, MA, USA), 
phosphospecific AMPK α subunit Thr172 (#2531; Cell Signaling Technology), 
phosphospecific insulin receptor substrate 1 (IRS1) Tyr612 (44-816G. Life 
Technologies, Carlsbad, CA, USA), IRS1 (06-248, Millipore, Billerica, MA, 
USA), phosphospecific Akt Ser473 (#9271; Cell Signaling Technology), Akt 
(#9272, Cell Signaling Technology), phosphospecific p70 ribosomal protein S6 
kinase (p70S6K) Thr389 (#9205, Cell Signaling Technology), p70S6K (#9202, 
Cell Signaling Technology), glucose transporter 4 (GLUT4) (4670-1704, 
Biogenesis, Poole, UK), and actin (#4968, Cell Signaling Technology). The 
membrane was then incubated with anti-rabbit IgG. Protein signals were 
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 developed using enhanced chemiluminescence (Millipore) and detected with 
ImageCapture G3 (Liponics, Tokyo, Japan). 
 
2.4. Isoform-specific AMPK activity assay 
AMPK comprises the catalytic α and regulatory β and γ subunits, and 
there are two distinct α subunits: α1 and α2 [8]. The kinase activities of 
α1-containing AMPK complex (AMPKα1) and α2-containing AMPK complex 
(AMPKα2) were measured as we have previously described [7]. Frozen 
muscles were homogenized in Buffer A, and the resultant supernatants (100 
µg protein) were incubated with either anti-α1 or -α2 antibody [7] and 
Protein A Sepharose beads (Amersham Biosciences, Uppsala, Sweden) at 4°C 
overnight. The beads were subjected to the kinase reaction using the SAMS 
peptide as a substrate. The kinase activity was expressed as incorporated 
ATP per min per immunoprecipitated protein. 
 
2.5. SAL transport and glucose transport assay 
SAL transport was measured using the double-isotope ([7-14C]salicylic 
acid and D-[1-3H(N)]mannitol) method. Muscles were preincubated and then 
incubated in KRB containing 5 mM [7-14C]salicylic acid (0.3 µCi/ml, 
American Radiolabeled Chemicals, St. Louis, MO) and 1 mM 
D-[1-3H(N)]mannitol (1.5 µCi/ml, American Radiolabeled Chemicals) at 37°C 
for up to 15 min. Muscles were then incubated in 1 M NaOH at 80°C for 10 
min. Digestates were neutralized with 1 M HCl, centrifuged at 20,000 g for 3 
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 min, and the radioactivity in the supernatant was measured by a scintillation 
counter. The intracellular space was determined as described [9], and the 
intracellular SAL concentration was calculated. 3-O-Methyl-D-glucose (3MG) 
transport was measured using the double-isotope ([3H]3MG and 
D-[1-14C]mannitol) method, as we have previously described [7]. The 
transport activity was expressed as 3MG taken up per intracellular space per 
hour. 
 
2.6. ATP, phosphocreatine (PCr), and glycogen assay 
ATP and PCr contents were measured enzymatically as we have 
described previously [10]. Glycogen content was measured using a glucose 
assay reagent (Glucose CII Test , Wako, Osaka, Japan) as we have previously 
described [11]. 
 
2.7. Statistical analysis 
Data are expressed as mean ± standard error (SE). Differences between 
two groups were compared with Student’s t test. Multiple means were 
analyzed using one-way ANOVA followed by post hoc comparison with 
Tukey’s or Dunnett’s test. P < 0.05 was considered significant. 
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 3. Results 
 
3.1. Effects of SAL on AMPK α subunit Thr172 phosphorylation and AMPK 
activity in skeletal muscles 
The Thr172 residue of the α subunit is the stimulatory phosphorylation 
site of AMPK [12]. We examined the phosphorylation status in both muscles. 
The dose-response study of AMPK phosphorylation showed significant 
increases by 2.4- and 2.7-fold in epitrochlearis muscle at concentrations of 5 
and 10 mM of SAL (30 min), and by 1.5-, 2.1-, and 2.2-fold in soleus muscle at 
concentrations of 1, 5, and 10 mM of SAL (30 min), respectively (Fig. 1A). The 
time-course study showed that 5 mM of SAL significantly phosphorylated 
AMPK after as little as 5 min in soleus and 15 min in epitrochlearis muscles 
(Fig. 1B). SAL did not change the total amount of AMPK. SAL (5 mM, 30 
min) increased the activity of both AMPKα1 and AMPKα2 by 4.1- and 
3.6-fold in epitrochlearis muscle, and by 2.1- and 2.4-fold in soleus, 
respectively (Fig. 1C). 
 
3.2. SAL uptake in skeletal muscles 
To our knowledge, no study has shown that SAL is taken up into skeletal 
muscle tissue. We found that the intracellular concentration of SAL 
increased rapidly in both epitrochlearis and soleus muscles in a 
time-dependent manner (Fig. 2A). The intracellular concentration of SAL 
was 3.1 ± 0.2 mM in epitrochlearis and 1.8 ± 0.1 mM in soleus at 15 min after 
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 the start of exposure to buffer containing 5 mM SAL. 
 
3.3. Effects of SAL on glucose transport and energy status in skeletal muscles 
AMPK is thought to act as a signaling molecule leading to an increase in 
insulin-independent glucose transport elicited by energy-depriving stresses 
in skeletal muscle [13,14]. The increased AMPK activity by SAL (5 mM, 30 
min) was associated with a 2.7-fold increase in 3MG transport in 
epitrochlearis muscle and a 4.2-fold increase in soleus muscle (Fig. 2B) 
compared with the basal conditions. Correspondingly, the contents of ATP, 
PCr, and glycogen were significantly lower in SAL-treated muscle samples 
than in the basal muscle samples for both epitrochlearis and soleus (Table 1). 
 
3.4. Effects of SAL on insulin signaling molecules in skeletal muscles 
The pharmacological inhibitor of oxidative phosphorylation, DNP, 
significantly phosphorylated AMPK in both muscles (Fig. 2C). The AMPK 
activator AICAR strongly phosphorylated AMPK in epitrochlearis and 
slightly phosphorylated AMPK in soleus, as we have previously reported [15]. 
By contrast, insulin did not phosphorylate AMPK in either muscle. Similar to 
DNP and AICAR, SAL did not increase the phosphorylation of insulin 
signaling molecules including IRS1, Akt, and p70S6K. SAL did not affect 
GLUT4 or actin content in either muscle. 
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 4. Discussion 
It has been suggested that skeletal muscle AMPK is involved in a variety 
of acute and chronic metabolic activation processes [16,17,18,19] such as 
insulin-independent glucose transport, fatty acid oxidation, glycogen 
regulation, expression of the GLUT4 glucose transporter, stimulation of 
peroxisome proliferator-activated receptor γ coactivator 1α, mitochondrial 
biogenesis, and enhanced insulin sensitivity. Besides exercise (contraction), 
there are a number of physiologically relevant stimuli of skeletal muscle 
AMPK, such as adipokines including leptin and adiponectin, antidiabetic 
drugs such as metformin and thiazolidinediones, and functional foods and 
their natural components [18,20,21]. In our earlier studies, we demonstrated 
that Morus alba leaf extract [22], caffeine [10], berberine [15], Coptidis 
rhizoma extract [23], and caffeic acid [24], all of which have been implicated 
as having antidiabetic properties, acutely (<30 min) promoted AMPK activity 
in isolated rat skeletal muscles. 
SAL has been shown to uncouple oxidative phosphorylation [1,25]. The 
SAL-induced decrease in ATP concentration has been documented in 
Drosophila melanogaster tissue culture (SL2) cells [26] and human 
neutrophils [27]. However, as far as we know, the present study is the first to 
demonstrate the ability of SAL to decrease the energy status in skeletal 
muscle. Interestingly, Hawley et al [4] showed that SAL is a direct AMPK 
activator that binds to the same site as the synthetic AMPK activator 
A-769662, which causes allosteric AMPK activation and inhibition of 
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 dephosphorylation of the α subunit Thr172. They also demonstrated that SAL 
promoted AMPK phosphorylation and activity in the absence of energy 
deprivation (an increase in ADP: ATP ratio) in HEK-293 cells [4]. Thus, SAL 
may stimulate AMPK via both energy-dependent and energy-independent 
processes in skeletal muscle. 
Hawley et al [4] found that oral SAL treatment for 2 weeks decreased 
fasting glucose concentration and improved insulin sensitivity and glucose 
tolerance in both the wild-type and AMPK β1 subunit knockout mice in a 
high fat diet-induced insulin-resistant condition. This seems to suggest that 
the effect of SAL on glucose metabolism is AMPK independent. However, 
Western blot analysis of rat tissues has revealed that the β1 subunit is most 
abundant in the liver and that little exists in skeletal muscle, whereas the β2 
subunit is most abundant in skeletal muscle and little exists in the liver [28] 
In fact, the β1-knockout mice had decreased AMPK activity in the liver but 
not in skeletal muscle [29]. Therefore, it is still possible that skeletal muscle 
AMPK plays an important role in mediating the effects of SAL on glucose 
homeostasis. 
The typical plasma concentration of SAL for clinical use is 0.95–1.9 mM, 
but the plasma concentration of free SAL falls in the range of <0.25 mM 
because of plasma protein binding of 80–90% [1]. Although we showed that 
the intracellular concentration of SAL increased rapidly after exposure to 
SAL (Fig. 2A), it is unlikely that a single oral dose of SAL is enough to induce 
substantial metabolic activation in skeletal muscle. As speculated from the 
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 finding of Goldfine et al [2] who demonstrated improved glycemic control 
after a 14-week SAL treatment in people with T2D, repeated SAL 
administration might contribute to a clinically relevant activation of AMPK 
in skeletal muscle. 
An advantage of using an isolated muscle preparation is that we could 
eliminate the confounding effects elicited by systemic administration of SAL. 
In particular, we considered the possibility that SAL inhibits IKKβ, an 
enzyme that is responsible for the activation of nuclear factor κ [30], and that 
evokes direct and/or indirect metabolic changes in skeletal muscle [31]. We 
used Western blotting to examine the inhibitory effect of SAL on IKKα/β 
phosphorylation in isolated muscles. However, because of the very low 
phosphorylation in the basal samples, we could not determine whether IKK 
phosphorylation decreased after SAL treatment in either muscle (data not 
shown). 
In summary, we report here for the first time that SAL was transported 
into muscle cells, where it increased both AMPKα1 and α2 activities, and 
glucose transport, and decreased muscle energy status. These effects 
occurred in both fast- and slow-twitch skeletal muscles. We propose that 
skeletal muscle AMPK is involved in the mechanism leading to the 
SAL-induced activation of glucose metabolism. 
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 Figure and table legends 
 
Fig. 1 SAL phosphorylates the α subunit Thr172, and stimulates both 
AMPKα1 and AMPKα2 activities in skeletal muscles. 
 (A) Epitrochlearis (EPI) and soleus (SOL) muscles were incubated with SAL 
(0–10 mM) for 30 min. The lysate was analyzed by Western blotting. Values 
are means ± SE; n = 6. **P < 0.01 vs. basal condition. Representative 
immunoblots are shown. (B) Muscles were incubated in the absence (basal) or 
presence of 5 mM SAL for 0–60 min. The lysate was analyzed by Western 
blotting. n = 6–10. **P < 0.01 and *P < 0.05 vs. basal. Representative 
immunoblots are shown. (C) Muscles were incubated with or without SAL (5 
mM) for 30 min, and α-isoform-specific AMPK activity was measured. Values 
are means ± SE; n = 6. ** P < 0.01 vs. basal condition. 
 
Fig. 2 SAL is transported into isolated skeletal muscles and stimulates 3MG 
transport without affecting insulin signaling in skeletal muscles. 
(A) Muscles were incubated with 5 mM SAL for 0–15 min. Intracellular SAL 
concentration was measured at each time point. Values are means ± SE; n = 
6–7. ** P < 0.01 vs. 0-min group. ## P < 0.01 vs. 5-min group. (B) Muscles 
were incubated with or without SAL (5 mM) for 30 min, and 3MG transport 
was measured. Values are means ± SE; n = 8–9. ** P < 0.01 vs. basal 
condition. (C) Muscles were incubated with or without SAL (5 mM) for 30 min, 
AICAR (2 mM) or insulin (1 µM) for 30 min, or DNP (0.5 mM) for 10 min, and 
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 analyzed by Western blotting. Representative immunoblots are shown. 
 
Table 1 
SAL decreases the energy status in skeletal muscles. 
Muscles were incubated with or without 5 mM SAL for 30 min. ATP, PCr, and 
glycogen contents were measured. Values are expressed as nmol/mg wet 
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Epitrochlearis ATP 4.4±0.2 2.3±0.3**
9.7±0.9**
12.0±1.1**
1.0±0.1**
2.5±0.4**
5.9±0.4**
17.2±0.7
19.1±0.8
2.0±0.2
7.6±0.9
11.7±0.3
PCr
glycogen
ATP
PCr
glycogen
Soleus
